Success Metrics

Clinical Success Rate
100.0%

Based on 6 completed trials

Completion Rate
100%(6/6)
Active Trials
4(36%)
Results Posted
33%(2 trials)

Phase Distribution

Ph phase_1
1
9%
Ph phase_3
8
73%
Ph phase_2
1
9%

Phase Distribution

1

Early Stage

1

Mid Stage

8

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
1(10.0%)
Phase 2Efficacy & side effects
1(10.0%)
Phase 3Large-scale testing
8(80.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

6 of 6 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

4

trials recruiting

Total Trials

11

all time

Status Distribution
Active(4)
Completed(6)
Other(1)

Detailed Status

Completed6
Active, not recruiting3
Recruiting1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
4
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (10.0%)
Phase 21 (10.0%)
Phase 38 (80.0%)

Trials by Status

recruiting19%
unknown19%
active_not_recruiting327%
completed655%

Recent Activity

4 active trials
Showing 5 of 11
recruitingphase_3

A Study of Olezarsen for the Treatment of Familial Chylomicronemia Syndrome (FCS) in Pediatric Participants

NCT07727538
completedphase_2

A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe Hypertriglyceridemia

NCT05355402
completedphase_3

A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe Hypertriglyceridemia

NCT05610280
completedphase_3

A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia

NCT05079919
active_not_recruitingphase_3

A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRX) Administered to Adults With Familial Chylomicronemia Syndrome (FCS) Previously Treated With Volanesorsen

NCT05185843
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT07727538Phase 3

A Study of Olezarsen for the Treatment of Familial Chylomicronemia Syndrome (FCS) in Pediatric Participants

Recruiting
NCT05355402Phase 2

A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe Hypertriglyceridemia

Completed
NCT05610280Phase 3

A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe Hypertriglyceridemia

Completed
NCT05079919Phase 3

A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia

Completed
NCT05185843Phase 3

A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRX) Administered to Adults With Familial Chylomicronemia Syndrome (FCS) Previously Treated With Volanesorsen

Active Not Recruiting
NCT05130450Phase 3

A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Participants With Familial Chylomicronemia Syndrome (FCS)

Active Not Recruiting
NCT05681351Phase 3

CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)

Active Not Recruiting
NCT05552326Phase 3

A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia

Completed
NCT04568434Phase 3

A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) Administered to Patients With Familial Chylomicronemia Syndrome (FCS)

Completed
NCT06360237

Olezarsen Early Access Program for Patients With Familial Chylomicronemia Syndrome (FCS)

Unknown
NCT05579860Phase 1

A Study Comparing Two Subcutaneous Formulations: Vial and Autoinjector (AI) With Olezarsen, at Two Dose Levels, in Healthy Adult Participants

Completed

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11